INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Peter Langmuir, MD
Incyte Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Asst Spedali Civili Di Brescia
Brescia, Italy
- Azienda Ospedaliera San Gerardo Di Monza
Monza, Italy
- Azienda Ospedaliera Universitaria Pisana
Pisa, Italy
- Ospedale Delle Croci - Ematologia Ravenna
Ravenna, Italy
- Hospital Germans Trias I Pujol
Badalona, Spain
- Hospital Clinic I Provincial
Barcelona, Spain
- Hospital General Universitari Vall D Hebron
Barcelona, Spain
- Fundacion Jimenez Diaz University Hospital
Madrid, Spain
- Hospital Universitario Hm Sanchinarro
Madrid, Spain
- Hospital Clinico Universitario de Salamanca
Salamanca, Spain
- Hospital Universitario Virgen del Rocio
Seville, Spain
- Hospital Universitario Y Politecnic la Fe
Valencia, Spain
- University of Arizona Cancer Center - Out Pt.
Tucson, Arizona, United States
- Indiana Blood and Marrow Transplantation
Indianapolis, Indiana, United States
- Comprehensive Cancer Center of Nevada
Las Vegas, Nevada, United States
- Texas Oncology
Austin, Texas, United States
- Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States
- Baylor College of Medicine
Houston, Texas, United States
- Smith Clinic
Houston, Texas, United States
- Cancer Care Centers of South Texas
San Antonio, Texas, United States
- Texas Oncology San Antonio
San Antonio, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 2 Jul 2018
- Primary completion
- 27 Jun 2022
- Completion
- 27 Jun 2022
- Last update posted
- 21 Aug 2025
- Registered enrollment
- 50
- Registry id
- NCT03424122
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.